Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical…
SPR206 shown to be well-tolerated; achieved lung exposures consistent with predicted therapeutic levels, when administered three times daily at 100 mg Results support further development of SPR206 in the setting of hospital-acquired…